Holen Sie sich die Stockscreener-App
1.9478
0.42%
0.0078
Schlusskurs vom Vortag:
$1.94
Offen:
$1.95
24-Stunden-Volumen:
533.89K
Relative Volume:
0.44
Marktkapitalisierung:
$188.26M
Einnahmen:
$11.16M
Nettoeinkommen (Verlust:
$-148.13M
KGV:
-1.2262
EPS:
-1.5885
Netto-Cashflow:
$-112.35M
1W Leistung:
+13.26%
1M Leistung:
+7.04%
6M Leistung:
-16.75%
1J Leistung:
+153.82%
1-Tages-Spanne:
$1.92
$2.005
1-Wochen-Bereich:
$1.80
$2.04
52-Wochen-Spanne:
$0.66
$3.535
Caribou Biosciences Inc Stock (CRBU) Company Profile
Firmenname
Caribou Biosciences Inc
Sektor
Branche
Telefon
510-982-6030
Adresse
2929 7TH STREET, SUITE 105, BERKELEY
Compare CRBU vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CRBU
Caribou Biosciences Inc
|
1.9481 | 187.48M | 11.16M | -148.13M | -112.35M | -1.5885 |
VRTX
Vertex Pharmaceuticals Inc
|
433.56 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
762.84 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
748.14 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
330.59 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.86 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Caribou Biosciences Inc Stock (CRBU) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-06-03 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2023-11-08 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2023-10-31 | Eingeleitet | Evercore ISI | Outperform |
| 2023-07-11 | Eingeleitet | Truist | Buy |
| 2022-02-18 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-12-01 | Eingeleitet | Oppenheimer | Outperform |
| 2021-11-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-11-15 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-08-17 | Eingeleitet | BofA Securities | Buy |
| 2021-08-17 | Eingeleitet | Citigroup | Neutral |
| 2021-08-17 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Caribou Biosciences Inc Aktie (CRBU) Neueste Nachrichten
Earnings Miss: How does Caribou Biosciences Inc compare to its peersWeekly Profit Report & Long-Term Capital Growth Strategies - baoquankhu1.vn
CRBU SEC FilingsCaribou Biosciences, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Caribou Biosciences, Inc. (CRBU) stock price, news, quote and history - sg.finance.yahoo.com
Alpha Cognition Inc. (ACOG) Jumps 8.6%: Does the Stock Have More Room to Grow? - Bitget
CRBU Stock Price, Quote & Chart | CARIBOU BIOSCIENCES INC (NASDAQ:CRBU) - ChartMill
Caribou Biosciences Granted FDA RMAT Designation for CB-011 Allogeneic Anti-BCMA CAR-T Cell Therapy - Minichart
Caribou Biosciences, Inc. Announces the FDA Granted Regenerative Medicine Advanced Therapy Designation to CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy - marketscreener.com
Caribou Biosciences Gains RMAT Status for CB-011 Therapy - tipranks.com
Caribou Biosciences Announces the FDA Granted Regenerative Medicine Advanced Therapy Designation to CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy - Investing News Network
Caribou Biosciences Announces the FDA Granted Regenerative Medicine Advanced Therapy (RMAT) Designation to CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy - Bitget
Caribou rises on FDA RMAT designation (CRBU:NASDAQ) - Seeking Alpha
Caribou Biosciences Announces The FDA Granted Regenerative Medicine Advanced Therapy (Rmat) Designation To Cb-011 - TradingView
Caribou Biosciences receives FDA RMAT designation for CB-011 in multiple myeloma - tradersunion.com
FDA grants RMAT designation to Caribou (CRBU) CAR-T CB-011 in multiple myeloma - Stock Titan
FDA gives advanced therapy status to Caribou's myeloma CAR-T - Stock Titan
Fed Watch: Can Caribou Biosciences Inc expand its profit marginsMarket Activity Recap & Daily Profit Maximizing Trade Tips - baoquankhu1.vn
Is Caribou Biosciences Inc a cyclical or defensive stockWeekly Trade Recap & High Conviction Buy Zone Picks - baoquankhu1.vn
Caribou Biosciences (NASDAQ:CRBU) Stock Rating Upgraded by Truist Financial - marketbeat.com
Hedge Fund Moves: Is Caribou Biosciences Inc stock good for income investors2026 Retail Activity & Daily Market Momentum Tracking - baoquankhu1.vn
How does Caribou Biosciences Inc compare to its peersPortfolio Gains Report & Fast Gaining Stock Reports - baoquankhu1.vn
Caribou Biosciences stock faces pressure amid biotech volatility and pipeline updates - AD HOC NEWS
Caribou Biosciences Shares Double After Strong Multiple Myeloma Trial Results - msn.com
Market Catalysts: Is Caribou Biosciences Inc benefiting from interest rate changesWeekly Risk Summary & Real-Time Buy Zone Alerts - baoquankhu1.vn
CRBU Earnings History & Surprises | EPS & Revenue Results | CARIBOU BIOSCIENCES INC (NASDAQ:CRBU) - ChartMill
Trading Action: How does Caribou Biosciences Inc compare to its peersInsider Buying & Risk Adjusted Buy/Sell Alerts - baoquankhu1.vn
Caribou Biosciences: Antlers Up For The Allogenic CAR-T Bet Trading At Cash Value - Seeking Alpha
Caribou Biosciences Teases vispa-cel Phase 3 LBCL Plan, Eyes Financing at Leerink Conference - MarketBeat
CRBU Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Analysts Are Bullish on Top Healthcare Stocks: Caribou Biosciences (CRBU), Oncology Institute (TOI) - The Globe and Mail
Drug Pricing Reforms Threaten Caribou Biosciences’ Future Margins and Market Access - The Globe and Mail
Caribou Biosciences: Advancing Allogeneic Cell Therapy Pipeline and Pivotal Trial Plans Support High-Risk Buy Rating - TipRanks
Truist reiterates Buy on Caribou Biosciences stock, $7 target - Investing.com Australia
Truist reiterates Buy on Caribou Biosciences stock, $7 target By Investing.com - Investing.com UK
Caribou Biosciences, Inc. (CRBU) reports Q4 loss, tops revenue estimates - MSN
Caribou Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - Investing News Network
Caribou Biosciences earnings beat by $0.04, revenue topped estimates - Investing.com Canada
Caribou Biosciences, Inc. (CRBU) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
Caribou Biosciences (NASDAQ:CRBU) Posts Earnings Results, Beats Estimates By $0.05 EPS - MarketBeat
Caribou Biosciences announces Q4 and FY2025 financial results - Traders Union
Caribou Biosciences Q4 licensing revenue rises, net loss narrows - TradingView
Insights into Caribou Biosciences Q4 Earnings - Benzinga
Caribou Biosciences, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
CRBU: Strong clinical progress and improved financials position the pipeline for pivotal trials - TradingView
Caribou Biosciences (Nasdaq: CRBU) details 2025 loss and CAR-T trial plans - Stock Titan
BRIEF-Caribou Biosciences Q4 Licensing And Collaboration Revenue USD 3.941 Million - TradingView
Caribou Biosciences Stock Soars Pre-market On Positive Early Trial Data For Cancer Treatments - Stocktwits
Cancer CAR-T developer Caribou has $142.8M to fund trials into 2H 2027 - Stock Titan
CRBU Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Caribou Biosciences (CRBU) to Release Earnings on Monday - MarketBeat
Insider Sell: Timothy Kelly Sells Shares of Caribou Biosciences Inc (CRBU) - GuruFocus
Caribou Biosciences Inc expected to post a loss of 31 cents a shareEarnings Preview - TradingView
Finanzdaten der Caribou Biosciences Inc-Aktie (CRBU)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.90%
1.08%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):